Avalanche Looks To Slow Snowball Effect With Annapurna Merger
This article was originally published in Scrip
Executive Summary
Avalanche Biotechnologies Inc. will acquire Annapurna Therapeutics SAS in an attempt to slow the snowball effect that wiped out 87% of Avalanche's value following disappointing clinical trial results for AVA-101 and a return to preclinical development for its lead gene therapy candidate.